{
    "nctId": "NCT04246671",
    "briefTitle": "TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer",
    "officialTitle": "Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Chordoma, HER2-positive Breast Cancer, HER2-positive Gastric/Gastroesophageal Junction Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 55,
    "primaryOutcomeMeasure": "Patients with Dose Limiting Toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\nGeneral inclusion criteria, apply to all cohorts:\n\n* Men and women \u226518 years old.\n* Patients must have histologically documented malignant tumor which is unresectable locally advanced or metastatic.\n* ECOG performance status 0 or 1\n* Patients must have normal organ and bone marrow function as defined in the protocol.\n* Normal left ventricular ejection fraction (LVEF) \u226550%.\n* Troponin I within normal limits.\n* A maximum cumulative dose of prior doxorubicin \u2264360 mg/m2 or epirubicin \u2264720 mg/m2\n* Any approved cancer therapy (except HER2 antibodies) must be completed at least 3 weeks or 5 half-lives for small molecule inhibitors, whichever is shorter, prior to the first planned dose of TVH vaccine.\n* Patients are required to be on active treatment with HER2 antibodies (trastuzumab, pertuzumab) prior to and during study treatment.\n* Patients must have recovered (Grade 1 or baseline) from any clinically significant toxicity associated with prior therapy.\n* Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1.\n\nExclusion Criteria:\n\n* Known metastatic disease to the central nervous system, unless previously treated and responded with a minimum stable disease over 2 CT scans separated at least 4 weeks from each other, and more than 6 weeks since the last dose of dexamethasone.\n* History of allergy or untoward reaction to prior vaccination with vaccinia virus, aminoglycoside antibiotics, ciprofloxacin, or egg products.\n* Subjects should have no known evidence of being immunocompromised.\n* Chronic administration (defined as \\>5 consecutive days of \\>15 mg of prednisone (or equivalent) per day) of systemic corticosteroids within 14 days of the first planned dose of TAEK-VAC-HerBy vaccine. Use of inhaled steroids, nasal sprays, eye drops, and topical creams is allowed. Steroids premedication for CT scans is allowed.\n* Clinically significant cardiomyopathy, coronary disease, congestive heart failure (NYHA class III or IV) or reduced as per institutional standards LVEF, poorly controlled hypertension (systolic \\>180 mm Hg or diastolic \\>100 mm Hg) or cerebrovascular accident within 1 year.\n* Known history of, or any evidence of active, non-infectious pneumonitis or primary pulmonary fibrosis.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}